The Third Central Hospital of Tianjin, Tianjin, China.
Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
BMC Med. 2024 Mar 6;22(1):101. doi: 10.1186/s12916-024-03315-0.
Non-alcoholic fatty liver disease (NAFLD) and metabolic-associated fatty liver disease (MAFLD) shares common pathophysiological mechanisms with type 2 diabetes, making them significant risk factors for type 2 diabetes. The present study aimed to assess the epidemiological feature of type 2 diabetes in patients with NAFLD or MAFLD at global levels.
Published studies were searched for terms that included type 2 diabetes, and NAFLD or MAFLD using PubMed, EMBASE, MEDLINE, and Web of Science databases from their inception to December 2022. The pooled global and regional prevalence and incidence density of type 2 diabetes in patients with NAFLD or MAFLD were evaluated using random-effects meta-analysis. Potential sources of heterogeneity were investigated using stratified meta-analysis and meta-regression.
A total of 395 studies (6,878,568 participants with NAFLD; 1,172,637 participants with MAFLD) from 40 countries or areas were included in the meta-analysis. The pooled prevalence of type 2 diabetes among NAFLD or MAFLD patients was 28.3% (95% confidence interval 25.2-31.6%) and 26.2% (23.9-28.6%) globally. The incidence density of type 2 diabetes in NAFLD or MAFLD patients was 24.6 per 1000-person year (20.7 to 29.2) and 26.9 per 1000-person year (7.3 to 44.4), respectively.
The present study describes the global prevalence and incidence of type 2 diabetes in patients with NAFLD or MAFLD. The study findings serve as a valuable resource to assess the global clinical and economic impact of type 2 diabetes in patients with NAFLD or MAFLD.
非酒精性脂肪性肝病（NAFLD）和代谢相关脂肪性肝病（MAFLD）与 2 型糖尿病具有共同的病理生理机制，因此成为 2 型糖尿病的重要危险因素。本研究旨在评估全球范围内 NAFLD 或 MAFLD 患者 2 型糖尿病的流行病学特征。
使用 PubMed、EMBASE、MEDLINE 和 Web of Science 数据库，以“2 型糖尿病”和“NAFLD 或 MAFLD”为检索词，检索了从成立到 2022 年 12 月发表的研究。采用随机效应荟萃分析评估了 NAFLD 或 MAFLD 患者 2 型糖尿病的全球和地区流行率和发生率密度。采用分层荟萃分析和荟萃回归分析探讨了异质性的潜在来源。
共纳入来自 40 个国家或地区的 395 项研究（6878568 例 NAFLD 患者，1172637 例 MAFLD 患者）。NAFLD 或 MAFLD 患者中 2 型糖尿病的总患病率为 28.3%（95%置信区间 25.2%-31.6%），全球范围内为 26.2%（23.9%-28.6%）。NAFLD 或 MAFLD 患者中 2 型糖尿病的发病率密度分别为 24.6/1000 人年（20.7-29.2）和 26.9/1000 人年（7.3-44.4）。
本研究描述了 NAFLD 或 MAFLD 患者中 2 型糖尿病的全球流行率和发病率。研究结果为评估 NAFLD 或 MAFLD 患者 2 型糖尿病的全球临床和经济影响提供了有价值的资源。
Zotero 插件
